Skip to Content

Besivance Approval History

  • FDA approved: Yes (First approved May 28th, 2009)
  • Brand name: Besivance
  • Generic name: besifloxacin
  • Dosage form: Ophthalmic Suspension
  • Company: Bausch & Lomb
  • Treatment for: Conjunctivitis, Bacterial

Besivance (besifloxacin ophthalmic suspension) is a topical quinolone antimicrobial for the treatment of bacterial conjunctivitis, commonly referred to as "pink eye."

Development History and FDA Approval Process for Besivance

May 29, 2009Approval Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye')
Dec  5, 2008FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.